Breaking News
Subscribe Now 0
👀 Ones to watch: Undervalued stocks to buy before they report Q3 earnings See Undervalued Stocks
Close

Check Cap Ltd (CHEK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Check Cap Ltd's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.3992 -0.0408    -2.83%
14:13:03 - Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 3,131
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.3992 - 1.4550
Check Cap Ltd 1.3992 -0.0408 -2.83%

Check Cap Ltd (CHEK) Earnings Dates & Reports

 
On this page, you can find detailed information about the financial performance of Check Cap Ltd, including the latest Check Cap Ltd earnings report and upcoming earnings date. The page provides an overview of the company's financial health, with key data points such as the current stock price, earnings per share, and revenue compared against the forecast.
Earnings Insights
Latest Release

Aug 01, 2024

EPS / Forecast

-- / -0.17

Revenue / Forecast

-- / --

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Feb 26, 2025 12/2024 -- /  -0.17 -- /  --
Nov 05, 2024 09/2024 -- /  -0.17 -- /  --
Aug 01, 2024 06/2024 -- /  -0.17 -- /  --
May 15, 2024 03/2024 -- /  -0.17 -- /  --
Apr 04, 2024 12/2023 -- /  -0.86 -- /  --
Nov 27, 2023 09/2023 -0.44 /  -0.44 -- /  --
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View upcoming earnings forecasts and in-depth analysis of company forecasts.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CHEK Comments

Write your thoughts about Check Cap Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
jyotsna singhal
jyotsna singhal Nov 28, 2022 3:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What’s going on really 🥹🥹🥹
Vladimir Ivanov
Vladimir Ivanov Aug 29, 2022 3:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$10 in few weeks! (after r/s)
Vladimir Ivanov
Vladimir Ivanov Jun 21, 2022 8:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
today is the day!
Sandeep Karwa
Sandeep Karwa Jun 21, 2022 8:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What is the good news ?
yesyes yes yes yes
yesyes yes yes yes Apr 21, 2022 7:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is an easy $2.50 stock on trials ending
Vincent Ornells
Vincent Ornells Apr 01, 2022 1:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Clinical trials begin April 15th 2022
Sandeep Karwa
Sandeep Karwa Apr 01, 2022 1:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How is the outlook short and long term ?
DEMOLITION MIND
DEMOLITION MIND Feb 07, 2022 10:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fda approval of pivotal study!!!
DEMOLITION MIND
DEMOLITION MIND Feb 01, 2022 8:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
We may see the moon soon
DEMOLITION MIND
DEMOLITION MIND Dec 09, 2021 3:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Countdown..
DEMOLITION MIND
DEMOLITION MIND Dec 03, 2021 4:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Com’oooon maaan!!!!
DEMOLITION MIND
DEMOLITION MIND Nov 25, 2021 2:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
For those new to Check Cap Here are some key pointsCheck Cap's C-Scan pill for colonoscopy has been approved for use in Isreal since 2018. https://www.prnewswire.com/news-releases/check-cap-receives-approval-from-the-israeli-ministry-of-health-to-initiate-commercial-sales-in-israel-of-its-c-scan-system-300706973.htmlCheck Cap's Scan tech requires no preparatory procedure which makes follow through with the procedure much easier and less impactful to individual's lives. Patients do not have to experience pain and discomfort from procedure like they do colonoscopies. They also do not need the same facility use as a colonoscopy allowing people to save time.The FDA is particularly interested in Chek because roughly 40% of Americans who should get a colonoscopies don't. Existing non-invasive colon screening is less acurate than C-scan Tech used by Check Cap.Recent study https://www.businesswire.com/news/home/20150428006203/en/New-Study-Reveals-People-Avoid-Colonoscopy
DEMOLITION MIND
DEMOLITION MIND Nov 25, 2021 2:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
28 percent do not feel it is necessary20.1 percent say it’s too expensive20.1 percent dislike the procedure itself (addressed by Check Cap)15.8 percent rely on other methods to avoid colon cancer (addressed by Check Cap)6.5 percent do not know they are supposed to get one6.5 percent are too busy with other priorities (addressed by Check Cap)Additionally Chek has already raised a large amount of capitolthis year that it expects will carry it through a stage 3 study for the US. Simplywall.st reports they should have enough capitol for 3 years of funding, but this does not account for large scale studies like a phase II and III trial. Covid delayed C-Scan US clinical testing as the FDA was unable to get to Israel in order to inspect the facility.Covid also highlighted challenges to Check Cap's supply chain as they previously used a single supplier, this is something management has been addressing and they have expressed confidence that their expansion and supply chain changes wi
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email